Drug-Induced Dilated Cardiomyopathy Associated with Anagrelide

Anagrelide, a phosphodiesterase inhibitor as a potent inhibitor of platelet aggregation, was approved by the FDA as oral treatment for essential thrombocythaemia and thrombocythaemia associated with polycythaemia vera. Common adverse effects of anagrelide include anemia, headache, dizziness, and diarrhea. Cardiovascular side effects are related to the inhibition of phosphodiesterase such as tachycardia, fluid retention and edema. However, anagrelideinduced cardiomyopathy is rare. We experienced a 73 yearsold man with essential thrombocythaemia developed anagrelide-induced dilated cardiomyopathy.